172875-98-8

Basic information

• Product Name: Dehydro Olmesartan
• Synonyms: Dehydro Olmesartan;4-(1-Methylethenyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-1H-iMidazole-5-carboxylic Acid;5-prop-1-en-2-yl-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid;Olmesartan Acid Anhydro Impurity;Olmesartan Dehydro;Olmesartan Impurity 21
• CAS NO: 172875-98-8
• Molecular Formula: C24H23N6O2
• Molecular Weight: 427.47842
• Product Categories: Aromatics;Bases & Related Reagents;Heterocycles;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals
• Mol File: 172875-98-8.mol

Chemical Properties

• Melting Point: >300°C (dec.)
• Boiling Point: 704.8±70.0 °C(Predicted)
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 2.23±0.50(Predicted)
• CAS DataBase Reference: Dehydro Olmesartan(CAS DataBase Reference)
• NIST Chemistry Reference: Dehydro Olmesartan(172875-98-8)
• EPA Substance Registry System: Dehydro Olmesartan(172875-98-8)

Safety Data

• Hazardous Substances Data: 172875-98-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Dehydro Olmesartan is used as a pharmaceutical agent for treating hypertension and other cardiovascular conditions. It functions as an angiotensin II receptor antagonist, which helps in lowering blood pressure by blocking the effects of angiotensin II, a hormone responsible for narrowing blood vessels.
Additionally, Dehydro Olmesartan may be used in research and development for the creation of new drugs targeting angiotensin II receptors, potentially leading to novel treatments for various cardiovascular diseases.

Upstream product

• 879562-26-2 (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl1-((2'-(1H-tetrazol-5-yl) biphenyl-4-yl)methyl)-4-(prop-1-en-2-yl)-2-propyl-1H-imidazole-5-carboxylate 
• 144689-63-4 olmesartan 
• 51802-42-7 2-propylimidazole-4,5-dicarbonitrile 
• 172875-70-6 5-Isopropenyl-2-propyl-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid ethyl ester 
• 144689-93-0 ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate 
• 144689-94-1 diethyl 2-(n-propyl)-1H-imidazole-4,5-dicarboxylate 
• 157356-73-5 ethyl 4-isopropenyl-2-propylimidazole-5-carboxylate 
• 58954-23-7 2-propyl-1H-imidazole-4,5-dicarboxylic acid 
• 172875-87-5 5-Isopropenyl-2-propyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid ethyl ester 

Downstream Products

• 1391052-99-5 (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-isopropenyl-2-propyl-1-[[2'-[2-(triphenylmethyl)-2H-tetrazol-5-yl]biphenyl-4-yl]methyl]imidazole-5-carboxylate 

Relevant articles and documents

METHOD OF PRODUCING RELATED SUBSTANCE OF OLMESARTAN MEDOXOMIL

The present invention refers to a formula 3, and 4 which is useful as a sterilizer olmesartan medoxomil flexible material of RNH6363 and RNH6373 relates to manufacturing method. The present invention refers to evaluating the quality product olmesartan medoxomil making n copies of the basic process by combining is selected from, amount of impurities on or touch manufacturing process second regions is made of a Pn which ask the password are displayed in quantifying the, manufacturing method of a known existing made more cheaply forming the, unit is off and can be easily manufactured.

Nonpeptide angiotensin II receptor antagonists: Synthesis, biological activities, and structure - Activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds

A series of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds were prepared and evaluated for their antagonistic activities to the angiotensin II (AII) receptor. Among them, the 4-(1-hydroxyalkyl)-imidazole derivatives had strong binding affinity to the AII receptor and potently inhibited the AII-induced pressor response by intravenous administration. Various esters of these acids showed potent and long-lasting antagonistic activity by oral administration. The most promising compounds were (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (CS-866) and (pivaloyloxy)-methyl esters of 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[(2′-1H-tetrazol-5-ylbiphenyl-4-yl) -methyl]imidazole-5-carboxylic acid (26c). A study involving stereochemical comparison of 26c with the acetylated C-terminal pentapeptide of AII was also undertaken.